Specialities: Dermatology · Oncology · Thoracic oncology
An anti–PD-1 monoclonal antibody formerly known as BMS-936558 (PMID 23714523). Approximate rate of pneumonitis is 3%, with 1% being severe (Grade 3/4). Incidence of pneumonitis is higher in those patients on concomitant nivolumab plus ipilimumab or other ICPI combo therapy (PMID 25891304)
Frequency - Incidence
Incidence of cardiac adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for cardiac adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
